Video

Clinical Pathways

Steven Peskin, MD, MBA, FACP: We have not embraced clinical pathways in the way that we’re saying that we’re working with a particular third-party clinical pathway company.

What we are doing is working around episode-of-care type of contracts. Within those clinical organizations, they are, in turn, setting certain standards and looking at certain pathways. They’re looking at their clinicians in their organizations [to see] if they’re following certain protocols—[for example, regarding] the judicious or injudicious use of PET/CT (positron emission tomography/computed tomography) scans, and which therapies are being used in what situations.

So we have not, as an organization, embraced a particular clinical pathway construct. Though we certainly see the great value in evidence-based care (evidence-based medicine), we’re not specifically focused on a particular clinical pathway, [having a] third party work with us, or [establishing] our own approach to designated clinical pathways.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Adela Perolla | Image Credit: - stock.adobe.com
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
4 experts are featured in this series.
2 experts in this video
Dr Ola Landgren
4 experts are featured in this series.
Dr Ola Landgren
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo